Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Open Access
- 22 July 2020
- preprint content
- Published by Cold Spring Harbor Laboratory
Abstract
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.Keywords
This publication has 31 references indexed in Scilit:
- Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptorCellular & Molecular Immunology, 2020
- Deployment of convalescent plasma for the prevention and treatment of COVID-19JCI Insight, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infectionPublished by Cold Spring Harbor Laboratory ,2020
- Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their ImplicationsSSRN Electronic Journal, 2020
- Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoirThe Journal of Experimental Medicine, 2019
- Data, disease and diplomacy: GISAID's innovative contribution to global healthGlobal Challenges, 2017
- CoronavirusesRNA Biology, 2011
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010